|
Report Highlights:
- A 6.4% increase in the total number of samples (including urine, non-ABP blood and dried blood spot samples) analyzed and reported into ADAMS in 2022 (256,770) vs. 2021 (241,430);
- An increase in the total percentage of AAFs year on year;
- An increase in the total number of samples analyzed and reported by most WADA-accredited laboratories and WADA-approved laboratories into ADAMS in 2022 vs 2021.
- An increase in the total number and percentage of non-ABP blood and DBS samples analyzed in 2022.
- An increase of 1.4% in the number of ABP blood samples analyzed in 2022.
- An increase in the total number of AAFs and % AAF for ERAs [including erythropoietin (EPO) and other EPO-receptor agonists], GHRFs and GC/C/IRMS tests in 2022.
The World Anti-Doping Agency (WADA) today publishes its 2022 Testing Figures Report (2022 Report), which summarizes the results of all the samples WADA-accredited laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2022.
The 2022 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples, blood and ABP blood data, and the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs).
WADA Director General Olivier Niggli said: “WADA’s Annual Testing Figures Report is the most comprehensive overview of all doping control samples analyzed and reported by WADA-accredited and WADA-approved laboratories around the world. WADA is pleased to note that the number of anti-doping tests in the testing figures continue to increase across the board and are the closest to the pre-pandemic levels (2019). An intelligence-led strategic in- and out-of competition testing plan is an important element of any strong anti-doping program and it is not the only angle of attack. Implemented along with values-based education, intelligence and investigations, and other strategies, testing is an important method of detection and deterrence that helps protect athletes and keep sport clean.
“The Testing Figures Report is an important tool for collaboration between Anti-Doping Organizations. The valuable data and information in the report provides ADOs with a key resource for strategy evaluation and for identifying potential patterns, best practices and areas of improvement. Anti-Doping Organizations are able to use the valuable intelligence contained within the Report to adapt their anti-doping programs and ensure that they are effective, intelligent and rooted in solid data.”
To help with the interpretation of the 2022 Report, a comprehensive Question and Answer document is available in the Related Documents section of the Anti-Doping Testing Figures Report page. Of particular importance, please note that:
- One single result does not necessarily correspond to one athlete. Results may correspond to multiple findings regarding the same athlete or measurements performed on the same athlete, such as in the case of longitudinal studies of testosterone.
- The number of AAFs in the Report may not correspond to the number of Anti-Doping Rule Violations (ADRVs) reported by Anti-Doping Organizations (ADOs). This is because all results are subject to a results management process conducted by ADOs, which includes matching results with Therapeutic Use Exemptions (TUEs), and longitudinal studies which can result in no case to answer or no sanction.
- The testing figures are generally published over a year later to provide enough time to collect and collate the large amount of data included in the report.
- As usual, this Report does not illustrate statistics on ADRVs, which are reported via a separate ADRV Report. The 2021 ADRV Report will be finalized and published in due course. The ADRV Report reveals analytical and non-analytical cases and the outcomes of results management, which is a process that can take a long time given that it may include investigations, appeals and other due processes.
|
